Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004132 · ClinicalTrials.gov registry record · Phase 2
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004132: Completed Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00004132 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004132, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of keratinocyte growth factor in preventing oral mucositis in patients who have hematologic cancers and who are undergoing radiation therapy and chemotherapy before autologous peripheral stem cell transplantation.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- BIOLOGICAL palifermin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-01 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
What the finished NCT00004132 record still lists
NCT00004132 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00004132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004132 about?
NCT00004132 is a clinical study titled "Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer". RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of keratinocyte growth factor in preventing oral mucositis in patients who have hematologic cancers and who...
What is the current status of trial NCT00004132?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-01. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00004132?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), palifermin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004132?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia